Bilateral internal thoracic artery grafting in insulin-treated diabetes

Oren Lev-Ran1, Menachem Matsa, Yaron Ishay

  • 1Department of Cardiothoracic Surgery, Soroka University Medical Center, Beer-Sheva, Israel.

Insights

Skeletonized bilateral internal thoracic artery grafts are safe for many insulin-treated diabetic patients, showing no increased sternal complications. However, these grafts do not offer midterm cardiac benefits compared to radial artery grafts.

Area of Science:

  • Cardiovascular Surgery
  • Diabetic Patient Management
  • Grafting Techniques

Background:

  • Assessing the safety and long-term outcomes of bilateral internal thoracic artery (BITA) grafting in insulin-treated diabetic patients.
  • Identifying specific subsets of diabetic patients eligible for BITA grafting.

Purpose of the Study:

  • To evaluate the risk and late outcomes of BITA grafting versus internal thoracic artery-radial artery (ITA-RA) grafting in insulin-treated diabetic patients.
  • To determine if BITA grafting is associated with increased sternal complications or improved cardiac outcomes in this population.

Main Methods:

  • A cohort of 147 insulin-treated diabetic patients undergoing arterial revascularization was analyzed.
  • Patients were divided into two groups: skeletonized BITA (n=83) and ITA-RA (n=64).
  • Exclusion criteria for BITA included chronic lung disease, overweight status, and being female.

Main Results:

  • BITA patients were younger and had fewer females; left-sided BITA configurations were common.
  • Deep sternal infection rates were 1.2% for BITA and 0% for ITA-RA; superficial wound infections were similar (3.1% vs 3.6%).
  • BITA grafting did not correlate with sternal complications (OR=2.24, p=0.256) and showed comparable 5-year survival, major adverse cardiac events, and mortality rates to ITA-RA grafting.

Conclusions:

  • Skeletonized BITA grafts can be safely used in a significant number of insulin-treated diabetic patients.
  • BITA grafting should not be automatically excluded but does not provide midterm cardiac benefits.
  • The choice of BITA grafting in this subset requires careful consideration of risks and benefits beyond immediate cardiac outcomes.
Abstract

Related Concept Videos